Arrowhead Pharmaceuticals Earnings
NASDAQ: ARWRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
62.75+2.01 (+3.31%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arrowhead Pharmaceuticals earnings summary
In its most recent report on Aug 4, 2026 (Q3 2026), ARWR posted EPS of $-1.36. Revenue for the quarter was $75.3 million. Across the last 16 reports, ARWR shares moved an average of 6.9% (in either direction) in the first trading session after results, rising 6 times and falling 10 times.
Summary generated from market data by MetaCap's automated system. Methodology
ARWR earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 4, 2026 | — | $-1.36 | — | -1.2% |
| May 7, 2026 | — | $-0.93 | — | +5.5% |
| Feb 5, 2026 | — | $0.22 | — | -1.1% |
| Nov 25, 2025 | — | $-0.11 | — | +16.6% |
| Aug 7, 2025 | — | $-1.26 | — | +24.9% |
| May 12, 2025 | — | $2.75 | — | -3.7% |
| Feb 10, 2025 | — | $-1.39 | — | -0.3% |
| Nov 26, 2024 | — | $-1.36 | — | -9.3% |
| Aug 8, 2024 | — | $-1.38 | — | -3.0% |
| May 9, 2024 | — | $-1.02 | — | +12.2% |
| Feb 6, 2024 | — | $-1.24 | — | -9.5% |
| Nov 29, 2023 | — | $-1.02 | — | +3.4% |
| Aug 7, 2023 | — | $-0.96 | — | -2.0% |
| May 2, 2023 | — | $0.45 | — | -5.0% |
| Feb 6, 2023 | — | $-0.39 | — | +1.9% |
| Nov 28, 2022 | — | $-0.80 | — | -10.9% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.